Agilon Health, Inc. (NYSE:AGL) Stock Now Rated “Hold” by Sell-Side Brokerages

Shares of Agilon Health, Inc. (NYSE:AGL) have received a consensus recommendation of “Hold” from the fourteen ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, six have given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $102.25.

AGL has been the subject of a number of research analyst reports. Benchmark restated a “buy” rating and set a $140.00 target price (up from $95.00) on shares of Agilon Health in a report on Thursday, August 6th. Truist Financial set a $112.00 price target on Agilon Health and gave the company a “hold” rating in a research note on Thursday, August 6th. Wells Fargo & Company restated an “overweight” rating and issued a $146.00 target price (up from $141.00) on shares of Agilon Health in a report on Tuesday, August 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a research note on Monday, August 24th. Finally, JPMorgan Chase & Co. upped their target price on shares of Agilon Health from $31.00 to $85.00 and gave the company an “underweight” rating in a report on Monday, August 24th.

Agilon Health Stock Performance

NYSE AGL opened at $112.59 on Friday. The stock has a 50-day moving average of $88.15 and a two-hundred day moving average of $66.73. Agilon Health has a 1-year low of $7.48 and a 1-year high of $133.04. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.08 and a quick ratio of 1.08. The company has a market cap of $1.89 billion, a P/E ratio of -20.29 and a beta of 3.10.

Agilon Health (NYSE:AGL) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $1.97 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.23) by $3.20. Agilon Health had a negative return on equity of 119.38% and a negative net margin of 3.92%. The company had revenue of $1.52 billion during the quarter, compared to analysts’ expectations of $1.46 billion. As a group, analysts anticipate that Agilon Health will post -2.90 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp purchased a new position in Agilon Health during the 2nd quarter worth $30,024,000. Rubicon Founders LLC bought a new stake in shares of Agilon Health during the 2nd quarter worth approximately $11,290,448. Bank of New York Mellon Corp lifted its stake in shares of Agilon Health by 9.5% in the second quarter. Bank of New York Mellon Corp now owns 35,336 shares of the company’s stock valued at $3,787,000 after buying an additional 3,074 shares in the last quarter. Tidal Investments LLC bought a new position in Agilon Health in the second quarter valued at $1,405,000. Finally, Ellsworth Advisors LLC purchased a new stake in shares of Agilon Health during the third quarter valued at $809,000.

About Agilon Health

Agilon Health, Inc is a healthcare company that partners with independent primary care physicians to support the transition from fee-for-service medicine to value-based care. The company works with physician practices serving primarily older adults enrolled in Medicare Advantage and helps them manage the cost, quality and coordination of care for their patient populations.

Agilon provides a technology-enabled platform that includes population health analytics, clinical and administrative support, care coordination resources and practice-management capabilities.